Bioss Inc., US), vimentin (bs-0756R, Bioss Inc., US), Oct4 (bs-1111R, Bioss
Inc., US), POLRMT (489004 Pab, USBiological, US), PARP1 (LS-C745005, LifeSpan
Biosciences Inc., US), ARV7 splice variant antibody (31-1109-00, RevMAb
Biosciences, US), BCR-ABL1 (ab187831, Abcam, US), BRAFv600E (31-1042-00, RevMAb
Biosciences, US), TrkA (ab76291, Abcam, US), TrkB (ab134155, Abcam, US), BRCA2
(N-terminus specific, ab75335, Abcam, US), and BRCA2 (C-terminus specific,
ARG10523, Arigo Biolaboratories Corp., US), pan cytokeratin (bs-1712R, Bioss
Inc., US), and KRAS 2B (16155-1-AP, Proteintech, US) were first modified with
streptavidin using a streptavidin conjugation kit (Abcam, US), according to the
manufacturer’s protocol. Briefly, 100 μL of the antibody solution
(1 mg mL−1) were gently shaken with 10 μL of the
activator. Afterward, the activated antibodies were incubated with 33 μg
streptavidin overnight at 4°C. Next, 10 μL of the quencher were
added to stop the reaction. Then, 80 μL of the biotin-labeled DNA (1 mg
mL−1) were added and the mixture was incubated at room
temperature for 30 min. Finally, the solution was stored at 4°C until
use.